Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.

Ulf LindströmBente GlintborgDaniela di GiuseppeTanja Schjødt JørgensenBjorn GudbjornssonKathrine Lederballe GrønSella Aarrestad ProvanBrigitte MichelsenMerete Lund HetlandJohan Karlsson WallmanDan NordströmNina TrokovicThorvardur Jon LoveNiels Steen KroghJohan AsklingLennart T H JacobssonLars Erik Kristensen

Published in: Rheumatology (Oxford, England) (2021)

No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
newly diagnosed
systemic lupus erythematosus
end stage renal disease
patient reported outcomes
disease activity